Term
|
Definition
| Relates a behavior to the activity of the brain and other organs. |
|
|
Term
|
Definition
| Describes the development of a structure or behavior. |
|
|
Term
|
Definition
| Reconstructs evolutionary history of a behavior or structure. |
|
|
Term
|
Definition
| Describes why a structure or behavior evolved as it did. |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Method of visualizing a living brain by injecting a dye into the blood and placing a person's head into a scanner. |
|
|
Term
| Magnetic Resonance Imaging |
|
Definition
| Method of imaging a living brain by using a magnetic field and a radio frequencey field to make actoms with odd atomic weights all rotate in the same direction and then removing those fields and measuring the energy that the atoms released. |
|
|
Term
|
Definition
| Measures the diffusion of water along the axons. |
|
|
Term
| In vivo direct recording of the brain |
|
Definition
|
|
Term
|
Definition
| A device that records electrical activity of the brain through electrodes attached to the scalp. |
|
|
Term
|
Definition
| A device that measures the faint magnetic fields generated by brain activity. |
|
|
Term
| In vivo indirect imaging of the brain |
|
Definition
|
|
Term
| Functional magentic resonance imaging |
|
Definition
| A modified version of MRI that measures energies based on hemoglobin instead of water. |
|
|
Term
| Positron-emission Topography |
|
Definition
| Method of mapping activity in a living brain by recording the emission of radioactivity from injected chemicals. |
|
|
Term
|
Definition
Wrap around the presynaptic terminal and take up chemicals from the axon.
Gets rid of waste
Influence blood vessels |
|
|
Term
|
Definition
| Primary function to remove waste material. |
|
|
Term
|
Definition
| Build myelin sheath in CNS |
|
|
Term
|
Definition
| Build the myelin sheath in the PNS. |
|
|
Term
|
Definition
Autoimmune Inflammatory Disease of CNS
Symptoms: Fatigue, numbness, loss of balance, visual disturbances, spasticity, depression and cognitive impairments.
Affects 1 in 1,000
Onset 30-50
Causes: Genetic predisposition, virus?, immune response
Treatments: Corticosteroids, Secondary groups |
|
|
Term
|
Definition
1. Synthesis: Neurotransmitters synthesized in presynaptic terminal
2. Release: Neurotransmitter released into synaptic cleft. Release is caused by the binding of Ca to synpatic vesicles.
3. Receptor: Neurotransmitter binds to receptors in postsynaptic membrane. Effect can be ionotropic or meabotropic.
4. Inactivation: Neurotransmitter separates from receptor. Then either reuptake, inactivation or negative feedback takes place.
|
|
|
